Treatment of Insomnia in Patients with Alzheimer's Disease

Recommended Treatment Approach

The American Geriatrics Society recommends that benzodiazepines should not be used as a first-line treatment for insomnia in patients with dementia due to an unacceptable risk-benefit ratio, with an increased risk of falls, cognitive impairment, dependence, and daytime sedation 1, 2
The American Academy of Sleep Medicine suggests that trazodone 50 mg or orexin receptor antagonists (suvorexant, lemborexant) may be considered for the treatment of insomnia in patients with Alzheimer's disease, with trazodone increasing total sleep time by 42.46 minutes (95% CI 0.9 to 84.0) and improving sleep efficiency by 8.53% (95% CI 1.9 to 15.1) 1, 2

Orexin receptor antagonists (suvorexant, lemborexant) have moderate-certainty evidence for increasing total sleep time by 28.2 minutes (95% CI 11.1 to 45.3) and reducing wake after sleep onset by 15.7 minutes (95% CI -28.1 to -3.3) in patients with mild to moderate Alzheimer's disease 1, 2
Melatonin (up to 10 mg) has low-certainty evidence showing little or no effect on primary sleep outcomes in patients with Alzheimer's disease, with no effect on total sleep time (MD 10.68 minutes, 95% CI -16.22 to 37.59) 1, 2

The treatment algorithm recommends starting with non-pharmacological interventions, such as sleep hygiene, sleep restriction, light exposure, physical and social activities, and considering pharmacotherapy only if these interventions are insufficient 1, 2
The algorithm also recommends avoiding benzodiazepines as a first-line treatment and using the lowest possible doses of medication, particularly in older adults who are more sensitive to adverse effects 1, 2

The American Geriatrics Society recommends maintaining stable bedtimes and rising times regardless of sleep obtained, limiting time in bed to match actual sleep time, using the bedroom only for sleep, ensuring adequate bright light exposure during the daytime, limiting or eliminating daytime napping, avoiding caffeine, evening alcohol, and late heavy meals, and implementing a consistent 30-minute relaxation period before bedtime in dementia patients 3
The American Academy of Sleep Medicine suggests limiting time in bed to match actual sleep time and limiting or eliminating daytime napping (if napping occurs, limit to 30 minutes before 2 PM) in dementia patients 4

The American Academy of Sleep Medicine recommends supplementing pharmacotherapy with behavioral therapy, as combined approaches are more effective and allow for lower medication doses in dementia patients 4, 5
Low-dose doxepin (3-6 mg) is suggested for sleep maintenance insomnia and may be considered in dementia patients, according to Praxis Medical Insights 6
The American Academy of Sleep Medicine advises against using benzodiazepines as first-line treatment in dementia patients due to unacceptable risk-benefit ratio, and instead recommends considering trazodone or melatonin while continuing behavioral strategies 4, 7

The American Academy of Sleep Medicine recommends reassessing every 2-4 weeks during active treatment and every 6 months thereafter, as relapse rates are high in dementia patients 4, 5

Deliver 3,000-5,000 lux of bright light exposure for 2 hours in the morning over 4 weeks to decrease daytime napping, increase nighttime sleep, reduce agitated behavior, and consolidate circadian rhythms in patients with dementia and insomnia, as recommended by the American Geriatrics Society 8
Ensure at least 30 minutes of sunlight exposure daily as part of the treatment regimen for patients with dementia and insomnia, according to the American Geriatrics Society 9
Implement structured physical and social activities during daytime hours to provide temporal cues that increase regularity of the sleep-wake schedule in patients with dementia and insomnia, as suggested by the American Geriatrics Society 8, 9
Minimize nighttime light and noise exposure, particularly in nursing home settings, to improve sleep quality in patients with dementia and insomnia, as recommended by the American Geriatrics Society 8, 9

Melatonin (up to 10 mg) may only be effective in patients with documented melatonin deficiency, according to the American Geriatrics Society 8, 9

Start with a comprehensive non-pharmacological approach (bright light therapy + structured activities + sleep hygiene) for 4-8 weeks in patients with dementia and insomnia, as recommended by the American Geriatrics Society 8, 9